Gina Chung is an Oncology physician affiliated with Christ Hospital. OpenAlex indexes 93 publications with 4,143 citations (h-index 26); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5885 Harrison Ave
Cincinnati, OH 45248
Telephone
513-588-5655Provider last certified this registry record 20 Nov 2024.
Clinical trials
- Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Sponsor: Yale University
Overall officialPhase 1CompletedNCT01640665 - Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Sponsor: Yale University
Overall officialPhase 2TerminatedNCT00461773
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20252 payments
- Exelixis Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
95.2%Iron, parenteral preparations94.6%Ferric carboxymaltose100%Part B, office-administered≥16 patientsFactor Xa inhibitor0.5%Eliquis80%Xarelto20%Part D<11 patients+ 1 more class in this area
Cancer & immunology
3.6%Aromatase Inhibitor2.6%Letrozole69%Anastrozole20%Exemestane11%Part D≥106 patientsEstrogen Agonist/Antagonist0.5%Tamoxifen Citrate100%Part D≥30 patients+ 3 more classes in this area
Nervous system
0.6%Opioid Agonist0.3%Oxycodone Hcl73%Morphine Sulfate Er27%Part D<11 patientsGabapentinoids0.2%Gabapentin68%Pregabalin32%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Emerson Perin, MD
Christ Hospital
Mickey Karram, MD
Christ Hospital
Wojciech Mazur, MD
Christ Hospital
Gregory Egnaczyk, MD
Christ Hospital
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”